Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The BPC-157 Pentadecapeptide Stack uses BPC-157 via two routes -- oral and injectable -- for comprehensive healing coverage. Oral BPC-157 (typically as arginine salt, BPC-157-Arginate) provides systemic gut healing, protects the GI mucosa, and offers whole-body anti-inflammatory effects via the gut-brain axis. Injectable BPC-157 targets specific injury sites through localized subcutaneous administration. By combining both routes, this protocol addresses gastrointestinal healing and musculoskeletal repair simultaneously, making it ideal for subjects with gut issues alongside physical injuries.
Oral BPC-157 (arginate salt) is acid-stable and directly contacts the gastrointestinal mucosa, providing localized healing for gut conditions including leaky gut, IBS, and gastric ulcers. It also exerts systemic effects through the gut-brain axis, modulating dopamine and serotonin systems, and provides whole-body anti-inflammatory benefits that complement injectable healing.
Subcutaneous BPC-157 concentrates healing activity at the injection site, directly promoting angiogenesis, growth factor upregulation, and tissue regeneration in musculoskeletal injuries. The dual-route approach ensures comprehensive coverage: oral for systemic/gut healing, injectable for targeted local repair at injury sites.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | BPC-157 oral 500mcg 2x/day | BPC-157 SubQ 250mcg 1x/day | AM oral+SubQ, PM oral | 6-8 weeks |
| Gut-Focus | BPC-157 oral 500mcg 2x/day | BPC-157 SubQ 250mcg EOD | AM/PM oral, AM SubQ | 6 weeks |
| Injury-Focus | BPC-157 oral 250mcg 1x/day | BPC-157 SubQ 500mcg 1x/day | AM oral, AM SubQ | 4-6 weeks |
BPC-157 has excellent safety across both oral and injectable routes.
| Panel | Markers | Timing |
|---|---|---|
| Inflammatory | CRP, ESR | Baseline, Week 4 |
| GI Markers | Calprotectin (stool), lactulose/mannitol | Baseline, Week 6 |
| Basic | CBC, CMP | Baseline, Week 4 |
Stool calprotectin tracks GI inflammation improvement. CRP and ESR track systemic inflammation from both routes.
For gut conditions (IBS, leaky gut, gastric ulcers), oral may be more effective due to direct mucosal contact. For musculoskeletal injuries, injectable near the injury site is superior. The combination leverages strengths of each route.
Yes, they are designed to be used together. They target different systems and the dual-route approach enhances overall healing. Take oral fasted and inject SubQ near injury site.
Oral BPC-157 primarily targets the GI tract with direct mucosal contact, while injectable targets specific injury sites with localized angiogenesis. Using both simultaneously addresses gut health and musculoskeletal healing at the same time.
For gut conditions (IBS, leaky gut, gastric ulcers), oral may be more effective due to direct mucosal contact. For musculoskeletal injuries, injectable near the injury site is superior. The combination leverages strengths of each route.
Yes, they are designed to be used together. They target different systems and the dual-route approach enhances overall healing. Take oral fasted and inject SubQ near injury site.
Oral BPC-157 primarily targets the GI tract with direct mucosal contact, while injectable targets specific injury sites with localized angiogenesis. Using both simultaneously addresses gut health and musculoskeletal healing at the same time.
For gut conditions (IBS, leaky gut, gastric ulcers), oral may be more effective due to direct mucosal contact. For musculoskeletal injuries, injectable near the injury site is superior. The combination leverages strengths of each route.
Yes, they are designed to be used together. They target different systems and the dual-route approach enhances overall healing. Take oral fasted and inject SubQ near injury site.